Founded in 2015, mynoise is the developer of the tinnitus app Kalmeda, the first and only fully approved behavioural therapy for chronic tinnitus with class 1 evidence. Since 2022, Kalmeda has been permanently recognised as a “digital health application” (DiGA) by the Federal Institute for Drugs and Medical Devices. Pohl-Boskamp has been distributing and marketing Kalmeda as a licensed product since 2020. Having acquired mynoise, Pohl-Boskamp can now ensure the continued existence of Kalmeda under its wing. Pohl-Boskamp has plans to develop further digital health applications and hopes the mynoise acquisition will strengthen its business and expertise in this field. GSK Stockmann provided comprehensive advice to Pohl-Boskamp on the acquisition with a team led by Hamburg M&A partner Max Wilmanns. Advisers of G. Pohl-Boskamp GmbH & Co. KG GSK Stockmann: Max Wilmanns (lead, M&A), Dominik Berka (Tax), Martin Hossenfelder (IP/IT); Associates: Christina Lorf (M&A), Sebastian Gerhards (Tax), Jonathan Jung (IP/IT) and Johanna Baumann (M&A).

---

16 MAY 2023